nivolumab,regorafenib
bms,bayer
[]
tomorrow at asco #gi23, dr. ruoyu miao shares results of a study investigating the biomarkers that can predict regorafenib and nivolumab treatment response in patients with refractory metastatic mismatch repair proficient (pmmr) colorectal cancer (crc). 
The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. News and stories at https://t.co/XaP6iv4q19.